Belmar Pharma Solutions: 503A + 503B compounder profile

Belmar is a national compounder best known for bioidentical hormone therapy, operating as both a 503A pharmacy and a 503B outsourcing facility. One attribution detail matters for anyone checking FDA records: Belmar’s 503B facilities are listed by their legal entity name, BSO LLC, not “Belmar.”

Facility & accreditation

Belmar describes itself as a national 503A compounding pharmacy and 503B outsourcing facility [2]. On the FDA Registered Outsourcing Facilities (503B) list, the matching entries are “BSO LLC, Golden, CO” (initial registration January 24, 2024) and “BSO LLC, Lakewood, CO” (initial registration November 24, 2015) [1]; the Belmar↔BSO link is corroborated by matching Colorado cities on both the FDA list and Belmar’s own facility pages. The company’s site lists NABP accreditation, a LegitScript certification, a California sterile license, and Alliance for Pharmacy Compounding membership, and says it serves practices in all 50 states [2] — these are the company’s own statements. Independently, we searched ACHC’s PCAB directory for both “Belmar” and “BSO” and found no PCAB accreditation listed [3]; NABP and LegitScript publish no self-service registry we could check in this review, so those badges remain unconfirmed from the accreditors’ own sources.

What they compound

A strong bioidentical-hormone (BHRT) focus — hormones, thyroid, hormone pellets — plus weight management and men’s/women’s wellness [2]. Named compounded GLP-1 (semaglutide/tirzepatide) product listings were not confirmed from the pages we reviewed.

Regulatory record

Per the FDA 503B list: the Golden, CO (BSO LLC) site was last inspected June 27, 2025, resulting in a Form 483, action status “Open”; the Lakewood, CO (BSO LLC) site was last inspected July 16, 2025, resulting in a Form 483, with an FDA “Regulatory Meeting Held” on March 3, 2026 and a flag indicating a prior compounding-related action in FDA’s history [1]. No warning letter is listed for either site in the current table. A Form 483 documents inspection observations, not a final finding; a regulatory meeting is a step FDA uses to discuss corrections. Dated to our review; status can change.

The read

A credible national hormone specialist with real 503B registration and 50-state reach. The two recent 483s and the Lakewood regulatory meeting are the items to track; the BSO-LLC naming is the practical gotcha when you go to verify anything in FDA records.

References

1. FDA — Registered Outsourcing Facilities (503B) list. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (accessed 2026-07-01)
2. Belmar Pharma Solutions — official site. https://www.belmarpharmasolutions.com/ (accessed 2026-07-01)
3. ACHC / PCAB accredited-organization directory (searched “Belmar” and “BSO”). https://organization.achc.org/ (accessed 2026-07-01)